Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
Journal of the International AIDS Society
|
November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
Josep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
The Lancet. HIV
|
January 15, 2016
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial
Samir K Gupta, Grace A McComsey, John Lombaard, et al.
HIV Medicine
|
March 21, 2025
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies
C Martorell, M Ramgopal, D Hagins, et al.
The Journal of Infectious Diseases
|
April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
Joseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
Debbie Hagins, Princy Kumar, Michael Saag, et al.
AIDS (London, England)
|
November 9, 2021
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, et al.
AIDS (London, England)
|
October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills, Gary J Richmond, Cheryl Newman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
Journal of the International AIDS Society
|
November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
Josep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
The Lancet. HIV
|
January 15, 2016
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial
Samir K Gupta, Grace A McComsey, John Lombaard, et al.
HIV Medicine
|
March 21, 2025
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies
C Martorell, M Ramgopal, D Hagins, et al.
The Journal of Infectious Diseases
|
April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab
Joseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study
Debbie Hagins, Princy Kumar, Michael Saag, et al.
AIDS (London, England)
|
November 9, 2021
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV
Lerato Mohapi, Yvett Pinedo, Olayemi Osiyemi, et al.
AIDS (London, England)
|
October 15, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills, Gary J Richmond, Cheryl Newman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
Josep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Lancet. HIV
|
April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Joel E Gallant, Eric S Daar, François Raffi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Page
of 6